Gwo Xi Stem Cell’s Novel Stroke Therapy GXNPC1 Published in the International Journal The ACTO Times

Gwo Xi Stem Cell’s novel stem cell therapy for stroke, GXNPC1^®, has had its latest research findings published in the international academic journal The ACTO Times (Vol. 2, Issue 4, Autumn 2025) under the title “Gwo Xi’s stem cell product GXNPC1 shows safety and beneficial effect for stroke patients.”

The study results demonstrate that no Suspected Unexpected Serious Adverse Reactions (SUSARs) were reported during the Phase I and Phase II clinical trials, supporting the favorable safety profile of GXNPC1^® following transplantation. Follow-up evaluations in patients with chronic stroke further suggested preliminary therapeutic efficacy. Stroke remains one of the leading causes of disability and mortality worldwide, and chronic stroke in particular represents a significant unmet medical need. Leveraging its proprietary Nigiro-Med^® technology platform, Gwo Xi Stem Cell enables GXNPC1^® to preserve high stem cell viability while promoting the expression of specific neurotrophic factors via preconditioning.

These findings not only validate the clinical applicability and therapeutic potential of stem cell therapy in stroke treatment, but reflect strong international academic recognition. Furthermore, they underscore Gwo Xi’s excellence in stem cell manufacturing processes, quality control systems, and clinical translation capabilities.

GXNPC1^® is currently advancing into Phase III clinical development while progressing toward commercialization. Following the anticipated implementation of Taiwan’s regenerative medicine regulatory framework in 2026, GXNPC1^® intends to apply for Conditional Approval to expedite market access. The company’s objective is for GXNPC1^® to become Taiwan’s first stem cell therapy to receive marketing approval upon Conditional Approval, thereby establishing a significant milestone in the development of the Taiwan cell therapy industry.

Looking forward, Gwo Xi remains committed to advancing stem cell therapy technologies and promoting clinical development, with the long-term objective of integrating regenerative medicine into routine clinical practice. Through these initiatives, the company aims to expand therapeutic options and address unmet clinical needs.

Source:
Published Journal: The ACTO Times, Vol. 2, Issue 4 (Autumn 2025 Edition)
Full Article Link: https://theactotimes.com/the-acto-times-vol-2-issue-4-2025-autumn-edition/